Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Preliminary Breakthrough Therapy Designation (BTD) Advice

<< Previous

Bullboard Posts

Next >>

Comment by CancerSlayeron Nov 01, 2024 5:39pm

198 Views

Post# 36293081

RE:RE:Preliminary Breakthrough Therapy Designation (BTD) Advice

The pre-BTD option certainly fine tunes the process & helps minimze the possibility of having to re-submit a BTD request in the event of a first-time denial (i.e. due to inadequate number of patients reported, inadequate data to support "preliminary clinical evidence"). This preliminary option takes a big burden off of the FDA & sponsor...would hate to have to file more than once. JMO.

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?